[Evaluation on HBeAg conversion time when treating chronic hepatitis B patients with combination of lamivudine and traditional Chinese medicine].
OBJECTIVE
To evaluate the effect of the combined use of traditional Chinese medicine and lamivudine (LMD) in treating chronic hepatitis B patients, and to follow the serological response for six months or longer.


METHODS
CNKI, Wanfang data, VIP data, CBMdisk, MEDLINE, EMBASE, BIOSIS and Cochrane Central Register of Controlled Trials database and literature were searched, to include randomized controlled trails (RCT) that used LMD alone or combined with traditional Chinese medicine. RevMan 4.2 was used for data analysis.


RESULTS
The Meta analysis of 7 trails demonstrated that the HBeAg conversion rate in treatment group was higher than those from the control group, and the differences were statistically significant at 6, 9, 12 months.


CONCLUSIONS
Data demonstrated that early intervention of traditional Chinese medicine might increase the HBeAg conversion rate but conclusion needs to be more specific to the types of trials.
Bai
Song-Lin
SL
The Department of Infection, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Hu
Xiao-Yu
XY
Zhong
Sen
S
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006513:Hepatitis B e Antigens / Q000097:blood* / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008516:Medicine, Chinese Traditional; D008517:Phytotherapy; D016032:Randomized Controlled Trials as Topic; D012698:Serologic Tests; D013997:Time Factors; D016896:Treatment Outcome
D000998:Antiviral Agents; D004365:Drugs, Chinese Herbal; D006513:Hepatitis B e Antigens; D019259:Lamivudine